Janssen Pharmaceutica develops treatment for patients worldwide in the following therapeutic areas of healthcare: Cardiovascular & Metabolism , Immunology , Infectious Diseases & Vaccines , Neuroscience , Oncology and Pulmonary Hypertension. Janssen partners with academic researchers, governments, patient groups, healthcare professionals, and others in their research. Janssen's activities range from initial basic research and production to commercial and support services and sale of medicines. Janssen Pharmaceutica operates as a subsidiary of Johnson & Johnson.
Janssen Pharmaceutica has been working with its parent company to create a medicine to aid with the COVID-19 pandemic. It is using non-replicating viral vector as well as Ad26 (alone or with modified vaccina Ankara boost) technology to conduct studies on how the vaccine can be used in the pandemic.
Ai Hua Ong
Company Group Chairman, Asia Pacific
Vice President and Chief Quality Officer, Pharmaceuticals
General Counsel, Pharmaceuticals
Jane Griffiths, Ph.D.
Global Head, Actelion
Chief Information Officer, Pharmaceuticals, Head of Enterprise Functions, Johnson & Johnson Technology
Executive Vice President Worldwide Chairman, Pharmaceuticals Johnson & Johnson
Vice Chairman of the Executive Committee Johnson & Johnson
Company Group Chairman, Europe, Middle East, and Africa
Head of Human Resources, Global, Pharmaceuticals Group and External Innovation
Global Lead, Pharmaceutical Communication & Public Affairs
Mathai Mammen, M.D., Ph.D.
Global Head, Research and Development
Global Head, Janssen Business Development
Paul Stoffels M.D.
Vice Chairman of the Executive Committee, Chief Scientific Officer Johnson & Johnson
Vice President, Group Finance, Pharmaceuticals
Vice President, Janssen Supply Chain
Richard Tillyer, Ph.D.
Global Head, Discovery, Product Development & Supply, Jannsen Research & Development
Company Group Chairman, North America Pharmaceuticals, Johnson & Johnson
Stef Heylen, M.D.
Chief Operating Officer, Development, Janssen Research & Development
Chief Executive Officer
Chief Operating Officer, Development
How one pharmaceutical company is reinventing the clinical trial - STAT
September 21, 2018
Janssen Pharmaceutical Companies Expands R&D at San Francisco, California Campus - Area Development
Area Development News Desk
January 13, 2020
Documentaries, videos and podcasts
2019 Dr. Paul Janssen Award Celebration
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- Cluster: Venture capitalA cluster of topics related to venture capital.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.